Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The allogeneic dilemma.

J L Harousseau1

  • 1Department of Hematology, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France. jean-luc.harousseau@univ-nantes.fr

Bone Marrow Transplantation
|August 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

Cancer treatment reviews·2016
Same author

Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Bone marrow transplantation·2015
Same journal

CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Bone marrow transplantation·2026
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026
Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
See all related articles

Allogeneic stem cell transplant (SCT) for multiple myeloma is debated due to toxicity. Reduced intensity conditioning (RIC) offers a safer option, showing improved survival over double autologous SCT by lowering relapse rates.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Immunology

Background:

  • Allogeneic stem cell transplantation (SCT) for multiple myeloma (MM) is controversial due to high toxicity with myeloablative regimens.
  • Toxicity limits its use to younger patients, with significant risks of infections and graft-versus-host disease (GVHD).
  • Reduced intensity conditioning (RIC) regimens offer lower transplant-related mortality, expanding eligibility to older patients.

Purpose of the Study:

  • To evaluate the efficacy of RIC allogeneic SCT in multiple myeloma management.
  • To compare RIC allotransplantation combined with autologous SCT against double autologous SCT.
  • To discuss the implications of recent findings on MM treatment strategies.

Main Methods:

  • Review of current literature on allogeneic SCT in multiple myeloma.

Related Experiment Videos

  • Analysis of a recently published Italian study comparing RIC allotransplantation strategies.
  • Discussion of transplant-related toxicity, GVHD, and relapse rates.

    • Main Results:

    • RIC regimens demonstrate lower transplant-related mortality, making them suitable for older patients.
    • RIC allotransplantation, when used after tumor debulking and high-dose therapy, shows reduced relapse rates.
    • This strategy resulted in better event-free survival compared to double autologous SCT in a recent Italian study.

    Conclusions:

    • RIC allotransplantation, particularly when integrated with autologous SCT, represents a promising strategy for multiple myeloma.
    • The reduced relapse rate associated with this approach offers an advantage over conventional double autologous SCT.
    • Further investigation is warranted to optimize the role of RIC allotransplantation in MM treatment protocols.